Form 4: Bicara Therapeutics CEO Sells Shares After Option Exercise

Bicara Therapeutics Inc. CEO Claire Mazumdar exercised stock options and subsequently sold 41,163 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Claire Mazumdar, Chief Executive Officer and Director of Bicara Therapeutics Inc. (BCAX), reported transactions on November 24, 2025.
• Exercised stock options to acquire 41,163 shares of common stock at an exercise price of $3.7898 per share.
• Subsequently sold 41,163 shares of common stock at a weighted average price of $18.8623 per share.
• The sale price for the shares ranged from $18.73 to $18.98, inclusive.
• Both the option exercise and the stock sale were executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
• Following these transactions, Ms. Mazumdar directly owns 309,892 shares of common stock and 236,107 stock options.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the CEO realized a significant profit from exercising options and selling shares. The transaction was pre-planned under a 10b5-1 plan, which mitigates negative interpretations of insider selling and suggests a routine management of equity compensation.

Positives

• The CEO realized a significant profit by exercising options at $3.7898 and selling shares at a weighted average of $18.8623.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not reactive sale, which can mitigate negative investor perception.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by some investors, potentially signaling a lack of future confidence, although this is often a routine part of executive compensation management.

Future Outlook

The filing primarily reports past transactions and does not contain explicit forward-looking statements or guidance, beyond the remaining vesting schedule of the stock options.

Industry Context

Insider transactions, particularly option exercises followed by sales, are common in the biotechnology and pharmaceutical industries, where executive compensation often includes significant equity components and stock options. These transactions are typically part of long-term compensation strategies and personal financial planning.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the CEO's profit positively as a sign of value creation, but some might interpret the sale as a signal, though the 10b5-1 plan suggests it is a routine, pre-planned event rather than a reaction to new information.

Next Steps

• The remaining 236,107 stock options will continue to vest in sixteen equal quarterly installments following August 8, 2023, subject to the reporting person's continued service.

Key Dates

Keywords

Bicara Therapeutics, BCAX, Claire Mazumdar, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, CEO, Director, Biotechnology